InMed Pharmaceuticals Inc.

For the period ended Jun 30, 2026. Filed Sep 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Sep 9, 2026

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	For the Year Ended
	June 30,
	2026	2025
	$	$
Operating Expenses
Research and development	3,028,473	2,821,202
General and administrative	6,661,372	5,414,525
Amortization and depreciation	205,271	210,443
Loss on disposal of equipment	7,136	-
Impairment of equipment	189,225	-
Impairment of intangible assets	1,457,926	-
Foreign exchange loss	58,009	28,471
Total operating expenses	11,607,412	8,474,641
Other Income (Expense)
Interest and other income	244,971	155,882
Finance expense	(10,700)	(371,549)
Loss from continuing operations before taxes	(11,373,141)	(8,690,308)
Income tax expense	-	-
Net loss from continuing operations	(11,373,141)	(8,690,308)
Discontinued operations:
Income (Loss) from discontinued operations	(1,187,709)	528,175
Income tax benefit	-	-
Income (Loss) from discontinued operations	(1,187,709)	528,175
Net Loss	(12,560,850)	(8,162,133)
Deemed dividends	(431,664)	-
Net loss attributable to common shareholders	(12,992,514)	(8,162,133)
Net loss per share for the year
Basic and diluted:
Continuing operations	(2.84)	(8.90)
Discontinued operations	(0.29)	0.54
Net loss per share attributable to Common Stockholders – basic and diluted	(3.12)	(8.36)
Weighted average outstanding common shares
Basic and diluted	4,163,598	975,895

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.